Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO5508887 · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| RO5508887 | EXPERIMENTAL | - |
| Part 1a | EXPERIMENTAL | - |
| Part 1b | PLACEBO_COMPARATOR | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Multiple doses of placebo |
| RO5508887 | DRUG | Multiple doses of RO5508887 |
Inclusion Criteria: * Adult healthy volunteers, \>/=18 years of age * Body mass index (BMI) between 18 and 30 kg/m2 inclusive * Use of adequate contraception methods or surgically sterile Exclusion Criteria: * Evidence of active or chronic disease * Regular consumption of drugs of abuse * Regular...
RO5508887 is an investigational small molecule developed by Roche Holding AG. It has been studied in Phase 1 clinical trials in healthy volunteers rather than in patients with a specific disease. No therapeutic indication for RO5508887 has been disclosed.
RO5508887 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche sponsored all three of the Phase 1 studies conducted with this compound.
RO5508887 is in Phase 1 development. All three of its recorded clinical trials were Phase 1 studies, and all three are now completed. The compound remains investigational and has not been approved by the FDA.
RO5508887 has been evaluated in three completed Phase 1 trials: NCT01664143 in France with 36 participants, NCT01592331 in the United States with 42 participants, and NCT01461967 in France with 49 participants. Together these studies enrolled 127 healthy volunteers.
The RO5508887 Phase 1 trials assessed safety, pharmacokinetics, and pharmacodynamics in healthy volunteers. NCT01461967 examined safety, pharmacokinetics, and pharmacodynamics; NCT01592331 focused on pharmacodynamic and pharmacokinetic measures; and NCT01664143 was a single-center study in healthy volunteers. All three were placebo-controlled and double-blind.